EPOPROSTENOL SODIUM

Post-LOE

epoprostenol sodium

GSK

ANDAINJECTIONINJECTABLE

Approved

Apr 2008

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

EPOPROSTENOL SODIUM (epoprostenol sodium) by GSK is 2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds and (2) inhibition of platelet aggregation. Approved for pulmonary arterial hypertension (pah) (who group i) to improve exercise capacity, hypertension. First approved in 2008.

Drug data last refreshed 19h ago

Mechanism of Action

2 major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds and (2) inhibition of platelet aggregation.

Indications (2)

pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity hypertension

Clinical Trials (1)

NCT01462565Phase 4Completed

Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)

Started Nov 2011

16 enrolled

Hypertension, Pulmonary

Worked on EPOPROSTENOL SODIUM at GSK? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.